BMS Presents Results of Deucravacitinib in Two P- III Trials for Moderate to Severe Plaque Psoriasis at AAD2021
BMS’ Abecma (Idecabtagene Vicleucel) Receives EC’s Conditional Approval for Relapsed and Refractory Multiple Myeloma
Shots:
- The two P-III POETYK PSO-1 and POETYK PSO-2 trials evaluating deucravacitinib (6mg, qd) vs PBO & Otezla (30mg, bid) @16wks. and vs Otezla @24wks. in 666 and 1,020 patients with the mod. to sev. plaque psoriasis respectively
- The trials met its co-1EPs & 2EPs i.e @16wks., PASI 75 (58.7% and 53.6%) vs (12.7% and 9.4%)& (35.1% and 40.2%) and @24wks. (69.0% and 59.3%) vs (38.1% and 37.8%), patients who achieved PASI 75, continued treatment with deucravacitinib (82.5% and 81.4%) and maintained it @52wks. respectively
- sPGA 0/1 response @16wks. (53.6% and 50.3%) vs (7.2% and 8.6%) & (32.1% and 34.3%) and @24wks (58.4% and 50.4%) vs (31.0% and 29.5%) respectively
Click here to read full press release/ article | Ref: BMS | Image: Fierce Biotech